↓ Skip to main content

Liposome-based drug delivery in breast cancer treatment

Overview of attention for article published in Breast Cancer Research, June 2002
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
384 Dimensions

Readers on

mendeley
374 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Liposome-based drug delivery in breast cancer treatment
Published in
Breast Cancer Research, June 2002
DOI 10.1186/bcr432
Pubmed ID
Authors

John W Park

Abstract

Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer agents. Long circulating macromolecular carriers such as liposomes can exploit the 'enhanced permeability and retention' effect for preferential extravasation from tumor vessels. Liposomal anthracyclines have achieved highly efficient drug encapsulation, resulting in significant anticancer activity with reduced cardiotoxicity, and include versions with greatly prolonged circulation such as liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has shown substantial efficacy in breast cancer treatment both as monotherapy and in combination with other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes and other ligand-directed constructs represent an integration of biological components capable of tumor recognition with delivery technologies.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 374 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 4 1%
United States 3 <1%
France 2 <1%
Iran, Islamic Republic of 2 <1%
Australia 1 <1%
United Kingdom 1 <1%
Lithuania 1 <1%
Germany 1 <1%
Spain 1 <1%
Other 3 <1%
Unknown 355 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 89 24%
Student > Master 76 20%
Student > Bachelor 41 11%
Researcher 32 9%
Student > Doctoral Student 19 5%
Other 56 15%
Unknown 61 16%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 52 14%
Agricultural and Biological Sciences 52 14%
Chemistry 50 13%
Pharmacology, Toxicology and Pharmaceutical Science 40 11%
Medicine and Dentistry 32 9%
Other 71 19%
Unknown 77 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2018.
All research outputs
#20,656,820
of 25,374,647 outputs
Outputs from Breast Cancer Research
#1,706
of 2,053 outputs
Outputs of similar age
#123,566
of 126,580 outputs
Outputs of similar age from Breast Cancer Research
#4
of 4 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 126,580 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.